What Marijuana Rescheduling Means — And Doesn't Mean — For DOT Drug Testing

Federal action to reclassify some marijuana products has raised questions for transportation employers: does rescheduling change DOT drug-testing rules or allow drivers to use medical marijuana without consequence? The short answer: not yet. Important agency distinctions and regulatory processes mean rescheduling is only the start of a longer compliance conversation for safety-sensitive transportation roles.

Key Federal Actions and Where They Stand

In December 2025, the President directed the Attorney General to accelerate rulemaking to consider moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. The Department of Transportation (DOT) quickly reiterated that, for DOT purposes, nothing had changed in its drug-testing rules at that time.

On April 28, 2026, the Drug Enforcement Administration (DEA) issued a final rule that placed FDA-approved drug products containing marijuana, along with marijuana and marijuana products dispensed under qualifying state medical-marijuana programs, into Schedule III. Meanwhile, a broader DEA rescheduling proceeding to transfer marijuana more generally from Schedule I to Schedule III continued, with formal hearings held June 29–July 15, 2026.

Rescheduling Is Not Legalization — Or An Automatic Prescription

Schedule III status does not legalize marijuana or turn state medical-marijuana authorizations into federally recognized prescriptions. Substances in Schedule III remain controlled under federal law. DOT, HHS and other federal agencies decide how scheduling changes affect federal programs, and those agencies may need additional regulatory or administrative steps to adjust existing frameworks.

DOT Testing Authority Remains Intact

DOT continues to assert authority to test for marijuana even if marijuana moves out of Schedule I. The department cites the Omnibus Transportation Employee Testing Act of 1991 and has told Congress that the Secretary's authority to test controlled substances is not strictly limited to Schedules I and II. In short: a broader rescheduling does not automatically remove DOT's statutory authority to require testing for substances that pose transportation-safety risks.

Practical Implementation Issues

Two technical issues are important. First, DOT's program relies on the Department of Health and Human Services (HHS) Mandatory Guidelines for Federal Workplace Drug Testing Programs and HHS-certified laboratories; portions of that framework are linked to specific schedule listings. Second, DOT and HHS will need to coordinate any necessary changes to testing panels, laboratory procedures, reporting and MRO processes if scheduling changes are broadened beyond the April 2026 action.

MROs, State Medical Marijuana Cards, And DOT Positives

Under DOT rules, a Medical Review Officer (MRO) must verify a confirmed marijuana positive unless the employee demonstrates a legitimate medical explanation. A valid federal prescription under the Controlled Substances Act can provide that explanation — a state-issued medical-marijuana card, dispensary receipt, or physician recommendation cannot.

Practical example: A commercial truck driver who tests positive and presents a state medical-marijuana card and dispensary records still faces a verified DOT positive. The MRO cannot convert that result to negative based on state authorization because state-dispensed marijuana is not FDA-approved and therefore not a federal prescription.

FMCSA Medical-Qualification Rules: A Separate, Open Question

Drug testing is only one compliance axis for commercial drivers. The Federal Motor Carrier Safety Administration (FMCSA) enforces medical-qualification standards under 49 C.F.R. § 391.41. Historically, FMCSA guidance has said drivers who use marijuana cannot meet federal medical-qualification standards because marijuana was a Schedule I substance. The regulation itself treats Schedule I substances differently from Schedules II–V: Schedule I use is prohibited, while some other schedules include a prescription exception when a licensed practitioner familiar with the driver’s history certifies no impairment.

As a result, a broader rescheduling could require FMCSA to clarify or revise how medical-qualification rules apply to marijuana products that move out of Schedule I. DOT's drug-testing guidance does not resolve how FMCSA will treat rescheduled marijuana for medical certification.

What Employers Should Do Now

• Continue existing DOT testing programs. Current rescheduling activity is not a lawful basis to suspend marijuana testing or change employer responses to verified positives.
• Do not accept state medical-marijuana cards as federal prescriptions. MROs and employers should follow DOT/HHS rules for verification and disposition.
• Monitor FMCSA, DOT and HHS guidance. Watch for technical changes to testing panels, laboratory certification or medical-qualification rules.
• Review policies for multistate workforces. State legalization does not change federal safety-sensitive requirements; employers must manage the resulting compliance patchwork.

Bottom Line

DEA actions on scheduling matter, but they are the beginning of a regulatory transition — not its end. DOT, HHS and FMCSA will determine how any rescheduling affects drug testing, laboratory procedures and medical fitness rules. For transportation employers, rescheduling starts the analysis; it does not finish it.

Originally published on Forbes.com.